Key facts
- This page summarizes Syed Ali-Aamir Rizvi's Form 4 filing for Poseida Therapeutics, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Apr 2024, 16:03.
Syed Ali-Aamir Rizvi - 01 Apr 2024 Form 4 Insider Report for Poseida Therapeutics, Inc.
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- N/A
- Reported as of
- 01 Apr 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Apr 2024, 16:03:59 UTC
- Prior SEC filing
- 23 Feb 2023
- Next SEC filing
- 08 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Harry J.Leonhardt, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Syed Ali-Aamir Rizvi filed Form 4 for Poseida Therapeutics, Inc. on 03 Apr 2024.
Change
- Previous filing in this sequence was filed on 23 Feb 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PSTX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +185,000
- Change %
- Price
- $0.000000
- Shares after
- 185,000
- Date
- 01 Apr 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PSTX
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +250,000
- Change %
- Price
- $0.000000
- Shares after
- 250,000
- Date
- 01 Apr 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 250,000
- Exercise price
- $3.10
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's 2022 Inducement Plan. The RSUs are scheduled to vest in four equal annual installments.
Footnote F2
12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date, and the remaining shares will vest in 42 equal monthly installments thereafter.